.Nature Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ enhanced bosom cancer and energetic or even steady mind metastases presented steady intracranial activity and wide spread efficiency of T-DXd.